| Ytd | 7.10% | |
| 1y | 342.31% |
| Open | 18.53 | Prev Close | 18.61 | Low | 18.02 | High | 18.64 | Mkt Cap | 1.33B |
| Vol | 478.85K | Avg Vol | 2.09M | EPS | 1.65 | P/E | 11.15 | Forward P/E | 16.25 |
| Beta | 2.54 | Short Ratio | 6.79 | Inst. Own | 50.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 12.66 | 200-d Avg | 11.85 | 1yr Est | 33.00 |
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the c
Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendat
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regu
Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% af
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's
Omeros Corp (OMER) shares rose 17.2% in pre-market trading after reporting better-than-expected Q2 r
Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly laun
Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estim
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market
Omeros (NASDAQ:OMER) reported quarterly earnings of $0.02 per share which beat the analyst consensus
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and de
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its f
Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) crossed above its two hundred day movi
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Med
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and tec
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation , (“
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Heartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data
LOS ANGELES, July 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights li
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regu
U.S. stocks slightly up, Dow Jones gains 0.1%. Health care shares jump 2.8%, ON Semiconductor down 2
HC Wainwright & Co. analyst Brandon Folkes maintains Omeros (NASDAQ:OMER) with a Buy and lowe
EMA rejects Omeros' Yartemlea for TA-TMA, citing insufficient efficacy data, despite FDA approva
Omeros Corporation (NASDAQ:OMER) announced today an update on the review by the Committee for Medici
Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-m
U.S. stock futures down, Nasdaq 100 futures drop over 1%. ON Semi to acquire Synaptics, ON shares fa
HC Wainwright & Co. analyst Brandon Folkes reiterates Omeros (NASDAQ:OMER) with a Buy and mai
HC Wainwright & Co. analyst Brandon Folkes reiterates Omeros (NASDAQ:OMER) with a Buy and mai
Omeros (NASDAQ:OMER) reported quarterly losses of $(0.24) per share which beat the analyst consensus
Omeros (NASDAQ:OMER) reported quarterly earnings of $3.14 per share which beat the analyst consensus
Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Adminis